Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	very long-chain fatty acid-CoA ligase activity	SLC27A5 SLC27A4	9.75e-05	10	30	2	GO:0031957
GeneOntologyMolecularFunction	transmembrane receptor protein tyrosine kinase activity	MST1R MET NTRK2	1.26e-04	65	30	3	GO:0004714
GeneOntologyMolecularFunction	superoxide-generating NAD(P)H oxidase activity	NCF2 DUOX1	1.43e-04	12	30	2	GO:0016175
GeneOntologyMolecularFunction	long-chain fatty acid-CoA ligase activity	SLC27A5 SLC27A4	2.26e-04	15	30	2	GO:0004467
GeneOntologyMolecularFunction	transmembrane receptor protein kinase activity	MST1R MET NTRK2	2.78e-04	85	30	3	GO:0019199
GeneOntologyMolecularFunction	long-chain fatty acid transmembrane transporter activity	SLC27A5 SLC27A4	3.29e-04	18	30	2	GO:0005324
GeneOntologyMolecularFunction	oxidoreductase activity, acting on NAD(P)H, oxygen as acceptor	NCF2 DUOX1	4.08e-04	20	30	2	GO:0050664
GeneOntologyMolecularFunction	DNA polymerase binding	CDT1 RTEL1	5.41e-04	23	30	2	GO:0070182
GeneOntologyMolecularFunction	fatty acid transmembrane transporter activity	SLC27A5 SLC27A4	5.41e-04	23	30	2	GO:0015245
GeneOntologyMolecularFunction	fatty acid ligase activity	SLC27A5 SLC27A4	6.93e-04	26	30	2	GO:0015645
GeneOntologyMolecularFunction	CoA-ligase activity	SLC27A5 SLC27A4	7.48e-04	27	30	2	GO:0016405
GeneOntologyMolecularFunction	acid-thiol ligase activity	SLC27A5 SLC27A4	9.88e-04	31	30	2	GO:0016878
GeneOntologyMolecularFunction	protein tyrosine kinase activity	MST1R MET NTRK2	1.32e-03	145	30	3	GO:0004713
GeneOntologyMolecularFunction	ligase activity, forming carbon-sulfur bonds	SLC27A5 SLC27A4	1.73e-03	41	30	2	GO:0016877
GeneOntologyMolecularFunction	carboxylic acid transmembrane transporter activity	SLC7A1 SLC27A5 SLC27A4	3.63e-03	207	30	3	GO:0046943
GeneOntologyMolecularFunction	organic acid transmembrane transporter activity	SLC7A1 SLC27A5 SLC27A4	3.68e-03	208	30	3	GO:0005342
GeneOntologyMolecularFunction	lipid transmembrane transporter activity	SLC27A5 SLC27A4	5.37e-03	73	30	2	GO:0170055
GeneOntologyMolecularFunction	monocarboxylic acid transmembrane transporter activity	SLC27A5 SLC27A4	8.05e-03	90	30	2	GO:0008028
GeneOntologyMolecularFunction	oxidoreductase activity, acting on NAD(P)H	NCF2 DUOX1	8.93e-03	95	30	2	GO:0016651
GeneOntologyMolecularFunction	organic anion transmembrane transporter activity	SLC7A1 SLC27A5 SLC27A4	9.47e-03	293	30	3	GO:0008514
GeneOntologyMolecularFunction	transcription coregulator activity	ACTN2 KAT2A SUFU TRIM5	9.52e-03	562	30	4	GO:0003712
GeneOntologyMolecularFunction	transcription coactivator activity	ACTN2 KAT2A TRIM5	1.04e-02	303	30	3	GO:0003713
GeneOntologyMolecularFunction	protein kinase activity	MST1R PHKA1 MET NTRK2	1.19e-02	600	30	4	GO:0004672
GeneOntologyMolecularFunction	ATP-dependent activity	RTEL1 DHX34 SLC27A5 SLC27A4	1.29e-02	614	30	4	GO:0140657
Domain	Tyr_kinase_HGF/MSP_rcpt	MST1R MET	2.67e-06	2	31	2	IPR016244
Domain	AMP-bd_C	SLC27A5 SLC27A4	3.57e-04	17	31	2	IPR025110
Domain	AMP-binding_C	SLC27A5 SLC27A4	3.57e-04	17	31	2	PF13193
Domain	TyrKc	MST1R MET NTRK2	4.13e-04	88	31	3	SM00219
Domain	Tyr_kinase_cat_dom	MST1R MET NTRK2	4.13e-04	88	31	3	IPR020635
Domain	PROTEIN_KINASE_TYR	MST1R MET NTRK2	5.49e-04	97	31	3	PS00109
Domain	Tyr_kinase_AS	MST1R MET NTRK2	5.49e-04	97	31	3	IPR008266
Domain	AMP-binding_CS	SLC27A5 SLC27A4	8.45e-04	26	31	2	IPR020845
Domain	IPT	MST1R MET	9.12e-04	27	31	2	SM00429
Domain	AMP_BINDING	SLC27A5 SLC27A4	9.81e-04	28	31	2	PS00455
Domain	AMP-binding	SLC27A5 SLC27A4	1.13e-03	30	31	2	PF00501
Domain	AMP-dep_Synth/Lig	SLC27A5 SLC27A4	1.13e-03	30	31	2	IPR000873
Domain	TIG	MST1R MET	1.20e-03	31	31	2	PF01833
Domain	SEMA	MST1R MET	1.20e-03	31	31	2	PS51004
Domain	Sema	MST1R MET	1.20e-03	31	31	2	SM00630
Domain	Semap_dom	MST1R MET	1.20e-03	31	31	2	IPR001627
Domain	Sema	MST1R MET	1.20e-03	31	31	2	PF01403
Domain	Pkinase_Tyr	MST1R MET NTRK2	1.26e-03	129	31	3	PF07714
Domain	Plexin_repeat	MST1R MET	1.28e-03	32	31	2	IPR002165
Domain	PSI	MST1R MET	1.28e-03	32	31	2	PF01437
Domain	IPT	MST1R MET	1.28e-03	32	31	2	IPR002909
Domain	Ser-Thr/Tyr_kinase_cat_dom	MST1R MET NTRK2	1.52e-03	138	31	3	IPR001245
Domain	DNA/RNA_helicase_DEAH_CS	RTEL1 DHX34	1.53e-03	35	31	2	IPR002464
Domain	DEAH_ATP_HELICASE	RTEL1 DHX34	1.81e-03	38	31	2	PS00690
Domain	-	MST1R MET WDR4 ATG16L2	2.14e-03	333	31	4	2.130.10.10
Domain	WD40/YVTN_repeat-like_dom	MST1R MET WDR4 ATG16L2	2.18e-03	335	31	4	IPR015943
Domain	PSI	MST1R MET	2.42e-03	44	31	2	IPR016201
Domain	PSI	MST1R MET	2.64e-03	46	31	2	SM00423
Pathway	KEGG_MEDICUS_REFERENCE_RTK_PLCG_ITPR_SIGNALING_PATHWAY	MST1R MET NTRK2	9.42e-05	55	23	3	M47952
Pubmed	Ron kinase transphosphorylation sustains MET oncogene addiction.	MST1R MET	8.73e-07	2	33	2	21212418
Pubmed	MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy.	MST1R MET	8.73e-07	2	33	2	32962738
Pubmed	Receptor tyrosine kinases MET and RON as prognostic factors in diffuse large B-cell lymphoma patients receiving R-CHOP.	MST1R MET	8.73e-07	2	33	2	23745832
Pubmed	MET is a predictive factor for late recurrence but not for overall survival of early stage hepatocellular carcinoma.	MST1R MET	8.73e-07	2	33	2	25874493
Pubmed	RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.	MST1R MET	8.73e-07	2	33	2	32324988
Pubmed	RON and c-Met facilitate metastasis through the ERK signaling pathway in prostate cancer cells.	MST1R MET	8.73e-07	2	33	2	28440432
Pubmed	c-Met and RON expression levels in endometrial adenocarcinoma tissue and their relationship with prognosis.	MST1R MET	8.73e-07	2	33	2	26189249
Pubmed	The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness.	MST1R MET	8.73e-07	2	33	2	12915129
Pubmed	MET and MST1R as prognostic factors for classical Hodgkin's lymphoma.	MST1R MET	8.73e-07	2	33	2	23558571
Pubmed	The Complete Loss of Tyrosine Kinase Receptors MET and RON Is a Poor Prognostic Factor in Patients with Extrahepatic Cholangiocarcinoma.	MST1R MET	8.73e-07	2	33	2	27919987
Pubmed	Cross-talk between the proto-oncogenes Met and Ron.	MST1R MET	2.62e-06	3	33	2	10871856
Pubmed	Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.	MST1R MET	2.62e-06	3	33	2	24628993
Pubmed	Specific Grb2-mediated interactions regulate clathrin-dependent endocytosis of the cMet-tyrosine kinase.	MST1R MET	2.62e-06	3	33	2	17449471
Pubmed	Activation of Wnt signaling in the intestinal mucosa of Apc +/min mice does not cause overexpression of the receptor tyrosine kinase Met.	MST1R MET	5.23e-06	4	33	2	16863504
Pubmed	PTPN23 ubiquitination by WDR4 suppresses EGFR and c-MET degradation to define a lung cancer therapeutic target.	MET WDR4	5.23e-06	4	33	2	37821451
Pubmed	Comparative characterization of the HGF/Met and MSP/Ron systems in primary pancreatic adenocarcinoma.	MST1R MET	5.23e-06	4	33	2	31254927
Pubmed	Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer.	MST1R MET NTRK2	7.51e-06	40	33	3	30898150
Pubmed	Interplay between scatter factor receptors and B plexins controls invasive growth.	MST1R MET	8.72e-06	5	33	2	15184888
Pubmed	A family of fatty acid transporters conserved from mycobacterium to man.	SLC27A5 SLC27A4	1.31e-05	6	33	2	9671728
Pubmed	Receptor tyrosine kinases fall into distinct classes based on their inferred signaling networks.	MET NTRK2	1.31e-05	6	33	2	23861540
Pubmed	Differential expression of fatty acid transport proteins in epidermis and skin appendages.	SLC27A5 SLC27A4	1.83e-05	7	33	2	16354187
Pubmed	X-linked adrenoleukodystrophy: role of very long-chain acyl-CoA synthetases.	SLC27A5 SLC27A4	2.44e-05	8	33	2	15464426
Pubmed	Genetic modifiers of EGFR dependence in non-small cell lung cancer.	MST1R NTRK2	3.13e-05	9	33	2	25512530
Pubmed	Genetic polymorphisms and susceptibility to lung disease.	NCF2 DUOX1	3.91e-05	10	33	2	16608528
Pubmed	A survey of protein tyrosine kinase mRNAs expressed in normal human melanocytes.	MST1R MET	4.78e-05	11	33	2	8247543
Pubmed	The expression and function of fatty acid transport protein-2 and -4 in the murine placenta.	SLC27A5 SLC27A4	5.73e-05	12	33	2	22028793
Pubmed	The protein tyrosine kinase family of the human genome.	MST1R MET NTRK2	6.79e-05	83	33	3	11114734
Pubmed	Ligand-activated peroxisome proliferator activated receptor gamma alters placental morphology and placental fatty acid uptake in mice.	SLC27A5 SLC27A4	7.89e-05	14	33	2	17463056
Pubmed	Hepatocyte growth factor-Met signaling is required for Runx1 extinction and peptidergic differentiation in primary nociceptive neurons.	MET NTRK2	7.89e-05	14	33	2	20844136
Pubmed	A role for p75 neurotrophin receptor in the control of hair follicle morphogenesis.	MET NTRK2	1.18e-04	17	33	2	10588868
Pubmed	Pericytes of Multiple Organs Do Not Behave as Mesenchymal Stem Cells In Vivo.	ACTN2 NTRK2	1.48e-04	19	33	2	28111199
Pubmed	Nutrient Transporter Gene Expression in the Early Conceptus-Implications From Two Mouse Models of Diabetic Pregnancy.	SLC27A5 SLC27A4	2.58e-04	25	33	2	35478964
Pubmed	Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis.	MST1R MET	3.25e-04	28	33	2	18593464
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	MST1R SLC7A1 KAT2A EPPK1 SUFU DHX34	5.39e-04	1105	33	6	35748872
Pubmed	Combinatorial CRISPR screen identifies fitness effects of gene paralogues.	MET KAT2A XPO7	7.30e-04	186	33	3	33637726
Pubmed	Quantitative proteomics identifies a Dab2/integrin module regulating cell migration.	MST1R MET	8.43e-04	45	33	2	19581412
Cytoband	11p15	OR6A2 TRIM5	4.44e-04	43	33	2	11p15
GeneFamily	Receptor Tyrosine Kinases\|CD molecules	MST1R MET NTRK2	2.23e-05	40	25	3	321
GeneFamily	Acyl-CoA synthetase family	SLC27A5 SLC27A4	5.85e-04	26	25	2	40
Coexpression	JAEGER_METASTASIS_DN	MST1R DUOX1 EPPK1 CHN2 NTRK2	1.49e-05	260	32	5	M10702
Drug	5H-benzo(4,5)cyclohepta(1,2-b)pyridin-5-one	MST1R MET NTRK2	1.26e-06	16	31	3	ctd:C561052
Drug	Benfotiamine [22457-89-2]; Up 200; 8.6uM; MCF7; HT_HG-U133A	MET SLC7A1 DHX34 IQSEC2 XPO7	6.36e-06	196	31	5	3837_UP
Drug	Pyrithyldione [77-04-3]; Up 200; 24uM; MCF7; HT_HG-U133A	MST1R MET RTEL1 NTRK2 IQSEC2	6.52e-06	197	31	5	6801_UP
Drug	PPAPs	SLC27A5 SLC27A4	5.00e-05	8	31	2	CID009576869
Drug	crizotinib	MST1R MET NTRK2	5.11e-05	53	31	3	ctd:C551994
Drug	AC1NUP8U	SLC27A5 SLC27A4	8.02e-05	10	31	2	CID005487216
Drug	nitrosamine	MST1R MET PTPN4	1.18e-04	70	31	3	CID000037183
Drug	LY 294002; Down 200; 10uM; MCF7; HT_HG-U133A	KAT2A WDR4 RTEL1 DHX34	1.19e-04	188	31	4	5224_DN
Drug	Gabazine [105538-73-6]; Down 200; 10.8uM; MCF7; HT_HG-U133A	SLC7A1 EPPK1 RTEL1 IQSEC2	1.24e-04	190	31	4	3253_DN
Drug	PHA-00846566E [724718-26-7]; Down 200; 10uM; PC3; HT_HG-U133A	MET EPPK1 RTEL1 DHX34	1.26e-04	191	31	4	7086_DN
Drug	Fenoterol hydrobromide [1944-12-3]; Down 200; 10.4uM; HL60; HT_HG-U133A	SLC7A1 RTEL1 DHX34 SLC27A5	1.29e-04	192	31	4	2378_DN
Drug	Dizocilpine maleate [77086-22-7]; Up 200; 11.8uM; MCF7; HT_HG-U133A	CHN2 RTEL1 NTRK2 IQSEC2	1.32e-04	193	31	4	6223_UP
Drug	Piperine [94-62-2]; Down 200; 14uM; MCF7; HT_HG-U133A	MET SLC7A1 RTEL1 TRIM5	1.32e-04	193	31	4	3263_DN
Drug	Eucatropine hydrochloride [536-93-6]; Down 200; 12.2uM; MCF7; HT_HG-U133A	MET SLC7A1 IQSEC2 XPO7	1.32e-04	193	31	4	3841_DN
Drug	Nortriptyline hydrochloride [894-71-3]; Up 200; 13.4uM; HL60; HT_HG-U133A	DUOX1 ACTN2 WDR4 DHX34	1.34e-04	194	31	4	2391_UP
Drug	Bumetanide [28395-03-1]; Down 200; 11uM; PC3; HT_HG-U133A	MET SLC7A1 EPPK1 WDR4	1.37e-04	195	31	4	5117_DN
Drug	Minaprine dihydrochloride [25953-17-7]; Up 200; 10.8uM; MCF7; HT_HG-U133A	SLC7A1 ACTN2 CHN2 NTRK2	1.37e-04	195	31	4	4814_UP
Drug	Clomiphene citrate (Z,E) [50-41-9]; Down 200; 6.6uM; MCF7; HT_HG-U133A	MET SLC7A1 WDR4 XPO7	1.37e-04	195	31	4	4994_DN
Drug	Mebhydroline 1,5-naphtalenedisulfonate [6153-33-9]; Down 200; 4.8uM; MCF7; HT_HG-U133A	MET SLC7A1 DHX34 IQSEC2	1.37e-04	195	31	4	3269_DN
Drug	GSK-3 Inhibitor IX; Up 200; 0.5uM; MCF7; HT_HG-U133A	KAT2A WDR4 DHX34 IQSEC2	1.37e-04	195	31	4	7101_UP
Drug	pheniramine	MST1R MET	1.39e-04	13	31	2	CID000004761
Drug	5253409; Down 200; 17uM; MCF7; HT_HG-U133A_EA	KAT2A WDR4 DHX34 TRIM5	1.40e-04	196	31	4	844_DN
Drug	Vidarabine [5536-17-4]; Up 200; 15uM; HL60; HT_HG-U133A	ACTN2 RTEL1 DHX34 IQSEC2	1.40e-04	196	31	4	2706_UP
Drug	Deltaline [6836-11-9]; Down 200; 7.8uM; MCF7; HT_HG-U133A	MET DHX34 TRIM5 IQSEC2	1.42e-04	197	31	4	6026_DN
Drug	Atracurium besylate [64228-81-5]; Down 200; 3.2uM; PC3; HT_HG-U133A	MET RTEL1 DHX34 XPO7	1.45e-04	198	31	4	1824_DN
Drug	Dantrolene sodium salt [14663-23-1]; Up 200; 11.8uM; PC3; HT_HG-U133A	MET ACTN2 NTRK2 IQSEC2	1.45e-04	198	31	4	4343_UP
Drug	Meclozine dihydrochloride [1104-22-9]; Up 200; 8.6uM; HL60; HT_HG-U133A	DUOX1 ACTN2 CHN2 NTRK2	1.45e-04	198	31	4	2424_UP
Drug	Tiabendazole [148-79-8]; Up 200; 19.8uM; HL60; HT_HG-U133A	MET ACTN2 CHN2 DHX34	1.45e-04	198	31	4	2479_UP
Drug	Azlocillin sodium salt [37091-65-9]; Up 200; 8.2uM; HL60; HT_HG-U133A	MET RTEL1 NTRK2 IQSEC2	1.45e-04	198	31	4	2727_UP
Drug	Neostigmine bromide [114-80-7]; Up 200; 13.2uM; HL60; HT_HG-U133A	MET SLC7A1 CHN2 DHX34	1.45e-04	198	31	4	2432_UP
Drug	Promazine hydrochloride [53-60-1]; Up 200; 12.4uM; HL60; HT_HG-U133A	MET WDR4 RTEL1 IQSEC2	1.45e-04	198	31	4	2173_UP
Drug	Triamterene [396-01-0]; Up 200; 15.8uM; HL60; HT_HG-U133A	CHN2 RTEL1 DHX34 NTRK2	1.45e-04	198	31	4	1861_UP
Drug	Dicumarol [66-76-2]; Up 200; 11.8uM; PC3; HT_HG-U133A	ACTN2 MUC2 NTRK2 IQSEC2	1.45e-04	198	31	4	4323_UP
Drug	Hesperidin [520-26-3]; Up 200; 6.6uM; MCF7; HT_HG-U133A	MST1R DUOX1 CHN2 IQSEC2	1.51e-04	200	31	4	2648_UP
Drug	Ramipril [87333-19-5]; Up 200; 9.6uM; HL60; HT_HG-U133A	MST1R DHX34 NTRK2 SLC27A5	1.51e-04	200	31	4	6150_UP
Drug	AND-CoA	KAT2A SLC27A5 SLC27A4	4.12e-04	107	31	3	CID003083159
Drug	POCA	SLC7A1 SLC27A4	5.71e-04	26	31	2	CID000054217
Drug	AC1L1947	SLC27A5 SLC27A4	5.71e-04	26	31	2	CID000000383
Drug	cypermethrin	NCF2 DUOX1 ERCC5 NTRK2	5.72e-04	284	31	4	ctd:C017160
Drug	L 012	NCF2 DUOX1	7.12e-04	29	31	2	CID000126741
Drug	Niacin	CHN2 NTRK2 SLC27A4	8.83e-04	139	31	3	ctd:D009525
Drug	cyproconazole	MET PCMTD1 NTRK2 ATG16L2	1.07e-03	336	31	4	ctd:C093628
Drug	lignoceroyl-CoA	SLC27A5 SLC27A4	1.29e-03	39	31	2	CID003082227
Drug	Coal Ash	MST1R SLC7A1 MUC2	1.30e-03	159	31	3	ctd:D060729
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	MET KAT2A DHX34	1.45e-03	165	31	3	5625_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A	CDT1 KAT2A DHX34	1.52e-03	168	31	3	6820_DN
Drug	hydroethidine	NCF2 DUOX1	1.64e-03	44	31	2	CID000065410
Drug	troglitazone; Up 200; 10uM; PC3; HT_HG-U133A	SLC7A1 WDR4 DHX34	1.66e-03	173	31	3	1232_UP
Drug	Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; PC3; HT_HG-U133A	EPPK1 CHN2 IQSEC2	1.66e-03	173	31	3	2105_UP
Drug	17-AAG; Up 200; 1uM; HL60; HT_HG-U133A	RTEL1 DHX34 NTRK2	1.68e-03	174	31	3	6177_UP
Drug	Clonidine hydrochloride [4205-91-8]; Up 200; 15uM; HL60; HG-U133A	NCF2 CHN2 NTRK2	1.77e-03	177	31	3	1555_UP
Drug	Heroin	ACTN2 NTRK2	1.79e-03	46	31	2	ctd:D003932
Drug	troglitazone; Up 200; 10uM; PC3; HT_HG-U133A	SLC7A1 PTPN4 MUC2	1.83e-03	179	31	3	4456_UP
Drug	Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; PC3; HT_HG-U133A	EPPK1 CHN2 NTRK2	1.86e-03	180	31	3	4072_UP
Drug	Etilefrine hydrochloride [534-87-2]; Up 200; 18.4uM; HL60; HT_HG-U133A	MET ACTN2 RTEL1	1.89e-03	181	31	3	2930_UP
Drug	15d-PGJ2; Up 200; 10uM; PC3; HT_HG-U133A	SLC7A1 PTPN4 ACTN2	1.95e-03	183	31	3	4455_UP
Drug	Rifabutin [72559-06-9]; Down 200; 4.8uM; MCF7; HT_HG-U133A	CDT1 RTEL1 DHX34	1.98e-03	184	31	3	4349_DN
Drug	Zm 241385	SLC7A1 NTRK2	2.03e-03	49	31	2	CID000176407
Drug	LY 294002; Down 200; 10uM; HL60; HT_HG-U133A	SLC7A1 DHX34 SLC27A5	2.04e-03	186	31	3	6198_DN
Drug	17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A_EA	EPPK1 WDR4 DHX34	2.04e-03	186	31	3	831_DN
Drug	Apigenin [520-36-5]; Down 200; 14.8uM; MCF7; HT_HG-U133A	MET DHX34 TRIM5	2.13e-03	189	31	3	4401_DN
Drug	15d-PGJ2; Up 200; 10uM; MCF7; HT_HG-U133A	MST1R SLC7A1 NCF2	2.16e-03	190	31	3	5591_UP
Drug	Naftopidil dihydrochloride [57149-08-3]; Up 200; 8.6uM; HL60; HT_HG-U133A	MET RTEL1 DHX34	2.16e-03	190	31	3	2911_UP
Drug	Fenbufen [36330-85-5]; Down 200; 15.8uM; PC3; HT_HG-U133A	MET SLC7A1 NTRK2	2.20e-03	191	31	3	4279_DN
Disease	Thromboembolism	TRIM5 NTRK2 ATG16L2	1.49e-05	44	32	3	HP_0001907
Disease	hypothyroidism (implicated_via_orthology)	PHKA1 DUOX1	8.82e-05	13	32	2	DOID:1459 (implicated_via_orthology)
Disease	pre-malignant neoplasm (biomarker_via_orthology)	SUFU MUC2	1.53e-04	17	32	2	DOID:0060071 (biomarker_via_orthology)
Disease	Chronic myeloproliferative disorder	CDT1 WDR4	1.93e-04	19	32	2	C1292778
Disease	Seckel syndrome	CDT1 WDR4	2.60e-04	22	32	2	C0265202
Disease	Pilocytic Astrocytoma	MET NTRK2	3.37e-04	25	32	2	C0334583
Disease	Cerebral Astrocytoma	MET NTRK2	3.37e-04	25	32	2	C0750935
Disease	Intracranial Astrocytoma	MET NTRK2	3.37e-04	25	32	2	C0750936
Disease	Astrocytoma	MET NTRK2	3.37e-04	25	32	2	C0004114
Disease	Juvenile Pilocytic Astrocytoma	MET NTRK2	3.37e-04	25	32	2	C0280783
Disease	Diffuse Astrocytoma	MET NTRK2	3.37e-04	25	32	2	C0280785
Disease	Grade I Astrocytoma	MET NTRK2	3.37e-04	25	32	2	C1704230
Disease	Subependymal Giant Cell Astrocytoma	MET NTRK2	3.37e-04	25	32	2	C0205768
Disease	Mixed oligoastrocytoma	MET NTRK2	3.37e-04	25	32	2	C0547065
Disease	Childhood Cerebral Astrocytoma	MET NTRK2	3.37e-04	25	32	2	C0338070
Disease	Gemistocytic astrocytoma	MET NTRK2	3.64e-04	26	32	2	C0334581
Disease	Protoplasmic astrocytoma	MET NTRK2	3.64e-04	26	32	2	C0334580
Disease	Fibrillary Astrocytoma	MET NTRK2	3.64e-04	26	32	2	C0334582
Disease	Anaplastic astrocytoma	MET NTRK2	3.93e-04	27	32	2	C0334579
Disease	melanoma (is_implicated_in)	ERCC5 RTEL1	6.25e-04	34	32	2	DOID:1909 (is_implicated_in)
Disease	autistic disorder (is_implicated_in)	MET NTRK2	9.55e-04	42	32	2	DOID:12849 (is_implicated_in)
Disease	colitis (biomarker_via_orthology)	MUC2 NTRK2	9.55e-04	42	32	2	DOID:0060180 (biomarker_via_orthology)

Protein segments in the cluster

Peptide	Gene	Start	Entry
QRYQIIPVCVAARLP	ATG16L2	311	Q8NAA4
RRELPPDQAQYCIKR	ACTN2	851	P35609
CPEQEQRLQRLERLP	CDT1	441	Q9H211
LPAVEQCLNRSLYRP	ANKRD36	336	A6QL64
CQAAQPEDRRVLRYP	CECR9	21	P0C854
DLQRVIANCREYNPP	KAT2A	796	Q92830
LIECNQPVYPLDIVR	PTPN4	871	P29074
CRPVLVYLQPGQIRV	DUOX1	656	Q9NRD9
CNYLEPVELRIHPQQ	NCF2	291	P19878
NRVPQPEYRQLLVEA	PHKA1	1116	P46020
CQLYEVPDPNRPQRL	IQSEC2	976	Q5JU85
PPCAVRNLQDLARIY	PCMTD1	236	Q96MG8
VPLEPYLRACQQDRC	MUC2	241	Q02817
LQQLPPQDIDERYCL	PRICKLE4	31	Q2TBC4
YQLQQEAPRPKRIIC	CHN2	31	P52757
LRQIQREPSLPQYEV	DHX34	261	Q14147
IVPLLNPIIYCLRNQ	OR6A2	286	O95222
PDRCVVQRLLPLTQY	HGH1	196	Q9BTY7
LLQGRRLLQPEYCPD	MET	1296	P08581
LCVEYEQEPVPARQR	RTEL1	816	Q9NZ71
QVRRENDLYVLPPLQ	ERCC5	136	P28715
NLTYVQLLRRCVPDP	EPPK1	3461	P58107
VLQRPRTCPQEVYEL	NTRK2	771	Q16620
PVCRISYQPENIRPN	TRIM5	56	Q9C035
ELCRYLLNQPPREAE	SLC27A4	336	Q6P1M0
LRYLCNIPQQPEDRT	SLC27A5	386	Q9Y2P5
CVLVLRYQPEQPNLV	SLC7A1	426	P30825
PCVRVPPNVLYEDLQ	FAM90A2P	436	Q658T7
CRRLYPDQPNPLQVT	SUFU	41	Q9UMX1
NPLPLEQRIDIRNYV	XPO7	76	Q9UIA9
LQDCQEAPLVLYRPV	WDR4	306	P57081
RQLPEQQLCRLPEYV	MST1R	816	Q04912
QQLCRLPEYVVRDPQ	MST1R	821	Q04912
CEQPLERRYQALPAL	TMEM198	26	Q66K66